Identification of two novel anti-fibrotic benzopyran compounds produced by engineered strains derived from streptomyces xiamenensis M1-94P that originated from deep-sea sediments

Marine Drugs

Volumn 11, Issue 10, 2013, Pages 4035-4049

  You, Zhong Yuan ^a   Wang, Ya Hui ^b   Zhang, Zhi Gang ^b   Xu, Min Juan ^c   Xie, Shu Jie ^d   Han, Tie Sheng ^a   Feng, Lei ^e   Li, Xue Gong ^a   Xu, Jun ^a  

^a Shanghai Jiao Tong University   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Chinese National Human Genome Center at Shanghai   (China)

^d SOA Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources Key Laboratory of Marine Genetic   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anti fibrosis; Benzopyran; Ribosome engineering; Streptomyces xiamenensis

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BENZOPYRAN DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; XIAMENMYCIN; XIAMENMYCIN C; XIAMENMYCIN D;

ANTI FIBROTIC ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CELL ENGINEERING; CELL PROLIFERATION; CONTROLLED STUDY; DEEP SEA; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROSIS; LUNG FIBROBLAST; NONHUMAN; RIBOSOME; RIBOSOME ENGINEERING; RPSL GENE; SEDIMENT; STREPTOMYCES; STREPTOMYCES XIAMENENSIS;

STREPTOMYCES;

BENZOPYRANS; FIBROBLASTS; FIBROSIS; GEOLOGIC SEDIMENTS; HUMANS; LUNG; MUTATION; RIBOSOMES; STREPTOMYCES; THREONINE;

EID: 84887112468     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11104035     Document Type: Article

References (27)

1. Vlietinck, A.J.; de Bruyne, T.; Apers, S.; Pieters, L.A. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med. 1998, 64, 97-109. (Pubitemid 28153266)
2. Borm, P. Toxicity of Selected: Toxicology of Fibers and Particles. In Proceedings of Toxicology and Risk Assessment, Heerlen, The Netherland, 14-17 April 2008; Greim, H., Snyder, R., Eds.; John Wiley & Sons Ltd.: Chichester, UK, 2008; pp. 565-583.
3. Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214, 199-210. (Pubitemid 351160157)
4. Friedman, S.L.; Sheppard, D.; Duffield, J.S.; Violette, S. Therapy for fibrotic diseases: Nearing the starting line. Sci. Transl. Med. 2013, 5, 1-17.
5. Wynn, T.A.; Ramalingam, T.R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 2012, 18, 1028-1040.
6. Machado, N.F.L.; Marques, M.P.M. Bioactive chromone derivatives - Structural diversity. Curr. Bioact. Compd. 2010, 6, 76-89.
7. Evans, J.M.; Fake, C.S.; Hamilton, T.C.; Poyser, R.H.; Watts, E.A. Synthesis and antihypertensive activity of substituted trans-4-amino-3, 4-dihydro-2, 2-dimethyl-2H-1-benzopyran-3-ols. J. Med. Chem. 1983, 26, 1582-1589. (Pubitemid 14245350)
8. Göker, H.; Boykin, D.W.; Yildiz, S. Synthesis and potent antimicrobial activity of some novel 2-phenyl or methyl-4H-1-benzopyran-4-ones carrying amidinobenzimidazoles. Bioorg. Med. Chem. 2005, 13, 1707-1714. (Pubitemid 40215258)
9. Kawamura, N.; Tsuji, E.; Watanabe, Y.; Tsuchihashi, K.; Takako, T. Benzopyran Derivatives, Their Manufacture with Streptomyces Species, and Their Use for Treatment of Asthma and Rheumatoid Arthritis. Jpn. Patent P2000-726766A, 7 March 2000.
10. Xu, J.; Wang, Y.; Xie, S.J.; Xiao, J.; Ruan, J.S. Streptomyces xiamenensis sp. nov., isolated from mangrove sediment. Int. J. Syst. Evol. Microbiol. 2009, 59, 472-476.
11. Xu, M.J.; Liu, X.J.; Zhao, Y.L.; Liu, D.; Xu, Z.H.; Lang, X.M.; Ao, P.; Lin, W.H.; Yang, S.L.; Zhang, Z.G.; et al. Identification and characterization of an anti-fibrotic benzopyran compound isolated from mangrove-derived Streptomyces xiamenensis. Mar. Drugs 2012, 10, 639-654.
12. Liu, X.J.; Xu, M.J.; Fan, S.T.; Wu, Z.; Li, J.; Yang, X.M.; Wang, Y.H.; Xu, J.; Zhang, Z.G. Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. J. Invest. Dermatol. 2013, 133, 1351-1360.
13. Nathan, C.; Ding, A.H. Nonresolving inflammation. Cell 2010, 140, 871-882.
14. Ochi, K. From microbial differentiation to ribosome engineering. Biosci. Biotechnol. Biochem. 2007, 71, 1373-1386. (Pubitemid 47012008)
15. Ochi, K.; Okamoto, S.; Tozawa, Y.; Inaoka, T.; Hosaka, T.; Xu, J.; Kurosawa, K. Ribosome engineering and secondary metabolite production. Adv. Appl. Microbiol. 2004, 56, 155-184. (Pubitemid 39574534)
16. Tanaka, Y.; Kasahara, K.; Hirose, Y.; Murakami, K.; Kugimiya, R.; Ochi, K. Activation and products of the cryptic secondary metabolite biosynthetic gene clusters by rifampin resistance (rpoB) mutations in actinomycetes. J. Bacteriol. 2013, 195, 2959-2570.
17. Ochi, K.; Hosaka, T. New strategies for drug discovery: Activation of silent or weakly expressed microbial gene clusters. Appl. Microbiol. Biotechnol. 2013, 97, 87-98.
18. Eckes, B.; Nischt, R.; Krieg, T. Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair 2010, 3, doi:10.1186/1755-1536- 3-4.
19. Wang, G.; Hosaka, T.; Ochi, K. Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations. Appl. Environ. Microbiol. 2008, 74, 2834-2340.
20. Xu, J.; Tozawa, Y.; Lai, C.; Hayashi, H.; Ochi, K. A rifampicin resistance mutation in the rpoB gene confers ppGpp-independent antibiotic production in Streptomyces coelicolor A3(2). Mol. Genet. Genomics 2002, 268, 179-189. (Pubitemid 35471769)
21. Okamoto-Hosoya, Y.; Okamoto, S.; Ochi, K. Development of antibiotic-overproducing strains by site-directed mutagenesis of the rpsL gene in Streptomyces lividans. Appl. Environ. Microbiol. 2003, 69, 4256-4259. (Pubitemid 36870091)
22. Hu, H.; Ochi, K. Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations. Appl. Environ. Microbiol. 2001, 67, 1885-1892. (Pubitemid 33644963)
23. Hesketh, A.; Ochi, K. A novel method for improving Streptomyces coelicolor A3(2) for production of actinorhodin by introduction of rpsL (encoding ribosomal protein S12) mutations conferring resistance to streptomycin. J. Antibiot. (Tokyo) 1997, 50, 532-535. (Pubitemid 27326744)
24. Okamoto-Hosoya, Y.; Sato, T.A.; Ochi, K. Resistance to paromomycin is conferred by rpsL mutations, accompanied by an enhanced antibiotic production in Streptomyces coelicolor A3(2). J. Antibiot. (Tokyo) 2000, 53, 1424-1427. (Pubitemid 32042474)
25. Shima, J.; Hesketh, A.; Okamoto, S.; Kawamoto, S.; Ochi, K. Induction of actinorhodin production by rpsL (encoding ribosomal protein S12) mutations that confer streptomycin resistance in Streptomyces lividans and Streptomyces coelicolor A3(2). J. Bacteriol. 1996, 178, 7276-7284. (Pubitemid 26424645)
26. Wilkinson, C.J.; Hughes-Thomas, Z.A.; Martin, C.J.; Bohm, I.; Mironenko, T.; Deacon, M.; Wheatcroft, M.; Wirtz, G.; Staunton, J.; Leadlay, P.F. Increasing the efficiency of heterologous promoters in actinomycetes. J. Mol. Microbiol. Biotechnol. 2002, 4, 417-426. (Pubitemid 34784704)
27. Kieser, T.; Bibb, M.J.; Buttner, M.J.; Chater, K.F.; Hopwood, D.A. Practical Streptomyces Genetics; John Innes Foundation: Norwich, UK, 2000.